A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Résumé

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Éligibilité

Conception de l'étude

Critères de jugement

1. Critère de jugement principal

   Disease Free Survival (DFS)

   DFS is measured as the time from randomization to the date of the first documented recurrence of Ta non-muscle invasive bladder cancer (NMIBC) of any grade, disease progression, or death due to any cause, whichever occurs first.

   Délai From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)

2. Critère de jugement secondaire

   Time to next Treatment (TTNT)

   TTNT is measured as the time from randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer.

   Délai From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)

3. Critère de jugement secondaire

   High Grade Recurrence-free Survival (HG RFS)

   HG RFS is measured as the time from randomization to the date of first documented evidence of HG NMIBC or death, whichever occurs first

   Délai From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)

4. Critère de jugement secondaire

   Progression Free Survival (PFS)

   PFS is measured as the time from randomization to the date of first documented evidence of disease progression or death, whichever occurs first.

   Délai From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)

5. Critère de jugement secondaire

   Number of Diagnostic and Therapeutic Invasive Urological Interventions after Study Treatment

   Number of diagnostic and therapeutic invasive urological interventions after study treatment, that is, endoscopic procedures (e.g., cystoscopies, transurethral resection of bladder tumors (TURBTs), ureteroscopies, urethral interventions, urethral stricture/bladder neck incision), catheterization (intravesical, suprapubic), intravesical treatments, major surgeries (e.g., radical cystectomy, simple cystectomy, urethroplasty) will be reported.

   Délai From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)

6. Critère de jugement secondaire

   Number of Participants With Adverse Events (Including Physical Examination, Vital Signs and Laboratory Abnormalities)

   An AE is any untoward medical occurrence in a participant participating in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product, that does not necessarily have a causal relationship with the treatment. AEs will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Severity of AEs has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening and Grade 5: Death. Number of participants with adverse events (including physical examination, vital signs and laboratory abnormalities) will be reported.

   Délai From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)

7. Critère de jugement secondaire

   Overall Survival (OS)

   OS is defined as the time from randomization to the date of death from any cause.

   Délai From randomization to the date of death (approximately 4 years and 2 months)

8. Critère de jugement secondaire

   European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire Core-30 items (EORTC-QLQ-C30) Scores

   EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity.

   Délai Baseline, Weeks 6, 12, 24, 36, and 48

9. Critère de jugement secondaire

   European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire for Non muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC24) Scores

   EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity.

   Délai Baseline, Weeks 6, 12, 24, 36, and 48

10. Critère de jugement secondaire

    Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-C30 Scores

    EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the HRQoL of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity.

    Délai Weeks 6, 12, 24, 36, and 48

11. Critère de jugement secondaire

    Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-NMIBC24 Scores

    EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity.

    Délai Weeks 6, 12, 24, 36, and 48

Dates

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

83 sites sont en recrutement

143 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

Aucun changement n'a été enregistré depuis que nous avons intégré cette fiche pour la première fois.

Un changement est enregistré chaque fois que le promoteur met à jour la fiche du registre. Le statut, les dates, le recrutement et les sites apparaissent ici au fur et à mesure de leur évolution.